Stock Ratings / Health Care / BWAY / dividends

SSII (39) CERS (37) DCTH (57) NPCE (30) ⌘ Pro Terminal →

BrainsWay Ltd. (BWAY) Dividend Safety Gauge & 10-Year DRIP Compounder

$11.93 +4.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

BrainsWay Ltd. (BWAY) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $478.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+1.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BWAY)Realized 20D OHLCV Swing Band: ±7.9%

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in BWAY & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on BWAY and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BWAY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.96%📐 HORIZONTAL RANGE

2026-10-30O $11.58H $11.93L $11.16C $11.93VOL 123.9K

RES: $17.44SUP: $10.87SMA50: $12.95SMA200: $13.92

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BWAY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BWAY Butterfly Map → + Track BWAY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BWAY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BWAY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BWAY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BWAY)

Health Care Rank #190 of 1016 ⚔️ SSII vs BWAY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BWAY vs. SSII, CERS, DCTH, NPCE)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BrainsWay Ltd. (BWAY) ranks #190 by composite RQD confidence (61/100, grade C-) and #461 by equity capitalization ($478.7M). Within this direct 5-issuer industry benchmark cohort, BWAY leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. BWAY currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BWAY ACTIVE BrainsWay Ltd.	C-	61/100	—	—	—	+4.93%	$478.7M	Benchmark Subject
SSII SS Innovations International Inc.	D-	39/100	—	46.0%	-18.5%	-2.46%	$477.2M	/ssii-vs-bway →
CERS Cerus Corporation	D-	37/100	—	—	-15.5%	+0.83%	$491.7M	/cers-vs-bway →
DCTH Delcath Systems Inc.	D+	57/100	—	86.2%	0.8%	-1.48%	$508.0M	/dcth-vs-bway →
NPCE Neuropace Inc.	E	30/100	—	77.2%	-23.0%	+0.62%	$446.6M	/npce-vs-bway →

2. BWAY Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

BrainsWay Ltd. (BWAY) operates in Medical/Dental Instruments (Health Care) with an equity capitalization of $478.7M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. BWAY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BWAY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, BrainsWay Ltd. (NASDAQ: BWAY) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $11.93 (+4.93% 1D, market cap $478.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, BWAY ranks #190 in composite RQD confidence.

How does BWAY compare to SSII and CERS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), BWAY carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SSII (SS Innovations International Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -18.5%, cap $477.2M) and CERS (Cerus Corporation) posts a D- grade (37/100 RQD, P/E N/A, ROIC -15.5%, cap $491.7M). Among the 5-stock peer group, BWAY leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BWAY?

For BrainsWay Ltd. (BWAY), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #190 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BWAY trading relative to its 50-day, 200-day, and 52-week technical levels?

BWAY last traded at $11.93 (+4.93% on volume of 121,745 shares), positioning the stock -7.88% below its 50-day simple moving average ($12.95) and -14.30% below its 200-day simple moving average ($13.92). Across its 52-week range of $7.14 to $17.40, BWAY sits at the 46.7% percentile with a 14-day RSI of 40.9 (NEUTRAL RANGE) and an implied next-earnings move of ±7.9% ($10.99 to $12.87).

BWAY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does BWAY pay a dividend and is it safe?

BrainsWay Ltd. (BWAY) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: BWAY RQD Cockpit BWAY 12M Forecast BWAY Earnings & Move BWAY Dividends & DRIP BWAY Insiders & 13F BWAY Whale Options BWAY Profit Sankey BWAY News & Why